Business Context and Reporting Period
This Form 8-K Current Report was filed by Enanta Pharmaceuticals, Inc. on August 19, 2021. The filing reports a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the expansion of the Board of Directors:
- Board Election: Yujiro S. Hata was elected as an independent director, effective August 19, 2021.
- Board Size: The total number of directors increased to seven.
- Committee Appointments: Mr. Hata was appointed to the Compensation Committee and the Nominating and Corporate Governance Committee.
- Term: His term expires at the 2024 annual meeting of stockholders.
Guidance, Outlook, and Compensation
The filing details the compensatory arrangements for the new director but provides no business outlook or risk factors:
- Cash Compensation: Mr. Hata will receive standard cash compensation for non-employee directors, including retainer fees for Board and committee service.
- Equity Grant: He received a non-statutory stock option to purchase 13,144 shares of Common Stock, vesting over 36 months.
- Indemnification: Mr. Hata is covered under the company's standard indemnification agreement for non-employee directors.
Investor Verification Checklist
- Verify the total number of directors on the Board is now seven.
- Confirm the vesting schedule of the 13,144 stock options granted to Mr. Hata.
- Review the company's standard director compensation policy to understand the cash retainer fees.
- Check the date of the next annual meeting of stockholders to confirm the 2024 expiration of Mr. Hata's term.